INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Javitt Jonathan C reported NRXP

Director, CEO and Chairman · NRX Pharmaceuticals, Inc. · NRX Pharmaceuticals, Inc. — Restricted Stock Unit

Side
A
Value
—
Shares
150.0K
Price
—
Executed
Jul 28, 2026
Disclosed
Nov 4, 2026
Disclosure timeline99 days from execution to publication · legal deadline 2 business days
Jul 28 executedNov 4, 2026 disclosed

NRXP · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+15 / 15

    Disclosed 71 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NRXP

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    24
    AS
    Abrams Michael SChief Financial Officer
    NRXPNRX Pharmaceuticals, Inc.
    Grant or award
    		A—
    75.0K sh
    		Jul 28, 2026Nov 4, 2026
    traded Jul 28, 2026
    		+99dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001437749-26-035009
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jul 28, 2026
    Published
    Nov 4, 2026
    Ingested by INSIDER
    Nov 5, 02:12 UTC
    Last re-read
    Nov 5, 15:28 UTC

    Extracted facts

    Filer
    Javitt Jonathan C
    Role
    Director, CEO and Chairman
    Transaction
    Grant or awardAs filed: “A”
    Asset
    NRX Pharmaceuticals, Inc. — Restricted Stock Unit
    Ticker
    NRXP
    Shares
    150.0K
    Price per share
    $0
    Execution date (reported)
    Jul 28, 2026
    Owned after transaction
    150.0K shares
    Days from execution to publication
    99

    What this establishes

    Javitt Jonathan C filed this Form 4 reporting a grant or award of NRXP on Jul 28, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO and Chairman
    Javitt Jonathan Ccik:0001303782
    Issuer
    NRX Pharmaceuticals, Inc.cik:0001719406

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.